NATCOPHARM.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 09:55):

NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs)...

Stats
Šios dienos apimtis	289 199
Vidutinė apimtis	1.02M
Rinkos kapitalizacija	180.61B
EPS	INR0 ( 2024-02-13 )
Kita pelno data	( INR0 ) 2024-05-27
Last Dividend	INR7.00 ( 2023-08-22 )
Next Dividend	INR0 ( N/A )
P/E	14.22
ATR14	INR0.562 (0.06%)

Tūris Koreliacija

Ilgas: 0.10 (neutral)

Trumpas: -0.87 (strong negative)

Signal:(41.648) Neutral

NATCO Pharma Limited Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

NATCO Pharma Limited Koreliacija - Valiuta/Žaliavos

-0.37
( neutral )

-0.18
( neutral )

-0.13
( neutral )

-0.54
( weak negative )

-0.13
( neutral )

0.60
( weak )

NATCO Pharma Limited Finansinės ataskaitos

Annual	2022
Pajamos:	INR27.07B
Bruto pelnas:	INR20.80B (76.83 %)
EPS:	INR39.18

FY	2022
Pajamos:	INR27.07B
Bruto pelnas:	INR20.80B (76.83 %)
EPS:	INR39.18

FY	2022
Pajamos:	INR19.05B
Bruto pelnas:	INR12.23B (64.22 %)
EPS:	INR9.32

FY	2021
Pajamos:	INR16.90B
Bruto pelnas:	INR10.82B (64.04 %)
EPS:	INR24.20

Financial Reports:

No articles found.

NATCO Pharma Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR3.50 (N/A)	INR0.750 (N/A)	INR1.250 (N/A)	INR0 (N/A)	INR7.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

NATCO Pharma Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 1.998 - low (50.00%) | Divividend Growth Potential Score: 3.27 - Decrease likely (34.51%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.200	1996-12-31
Last Dividend	INR7.00	2023-08-22
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	33	--
Total Paid Out	INR56.90	--
Avg. Dividend % Per Year	0.68%	--
Score	2.39	--
Div. Sustainability Score	1.998
Div.Growth Potential Score	3.27
Div. Directional Score	2.64	--

Next Divdend (Est)
(2024-07-24)

INR7.62 Estimate 6.47 %

Dividend Stability

0.26 Very Poor

Dividend Score

2.39

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
1996	INR0	0.00%
1997	INR0	0.00%
1998	INR0	0.00%
1999	INR0	0.00%
2000	INR0	0.00%
2001	INR0	0.00%
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR8.50	1.07%
2019	INR7.00	1.01%
2020	INR8.75	1.42%
2021	INR3.50	0.36%
2022	INR6.25	0.68%
2023	INR8.25	1.49%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SANDHAR.NS	Dividend Junior	2023-09-14	Annually	7	0.66%
LXCHEM.NS	Dividend Junior	2023-07-20	Annually	4	0.11%
GLENMARK.NS	Dividend Junior	2023-09-18	Annually	23	0.37%
ASIANPAINT.NS	Dividend Junior	2023-06-09	Semi-Annually	23	0.43%
TINPLATE.NS	Dividend Junior	2023-08-11	Annually	19	0.72%
PDMJEPAPER.NS	Dividend Junior	2023-08-03	Annually	9	0.65%
J&KBANK.NS	Dividend Junior	2023-08-17	Sporadic	22	0.47%
DATAMATICS.NS	Dividend Junior	2023-09-22	Annually	21	0.49%
SHYAMMETL.NS	Dividend Junior	2023-06-05	Semi-Annually	4	0.70%
MAXHEALTH.NS	Dividend Junior	2023-09-08	Insufficient data to determine frequency	2	0.07%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.334	1.500	3.32	4.99	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.251	1.500	8.32	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	97.83	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	19.24	2.00	3.59	7.17	[0 - 30]
freeCashFlowPerShareTTM	19.24	2.00	0.380	0.760	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.783	1.000	0.290	0.290	[0.2 - 0.8]
operatingProfitMarginTTM	0.401	1.000	3.98	3.98	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				1.998

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	14.41	1.000	8.65	0	[1 - 100]
returnOnEquityTTM	0.251	2.50	8.92	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	19.24	2.00	3.59	0.760	[0 - 30]
dividendYielPercentageTTM	0.924	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	19.24	2.00	3.59	7.17	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-3.23	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0900	1.000	-0.250	0	[0.1 - 0.5]
Total Score				3.27

NATCO Pharma Limited

NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF. The company markets its products in approximately 40 countries, including India, the United States, and internationally. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.